Cardiovascular Health

These therapies represent an encouraging advancement in cardiovascular care.

The sessions will include late-breaking science, clinical practice guidelines, early innovators spotlight sessions, and more.

Insomnia exhibits a dose-response relationship with AF recurrence, indicating that an increased number of insomnia symptoms is associated with heightened probability of AF recurrence.

The novel therapy demonstrated safety and efficacy in a clinical trial.

Historically, colchicine has been used primarily in the management of gout; however, in 2023, the FDA approved Lodoco, a newly marketed colchicine product, for the management of cardiovascular disease.

Higher doses of β-blockers are associated with better clinical outcomes in patient with heart failure.

Endometriosis is a systemic disease that can affect multiple parts of the body, not just the pelvis.

Cardiovascular diseases have a significant impact on brain health and function.

Current guidelines recommend a backbone of SLGT2 therapy in patients with HFpEF who have no contraindications.

AI-enabled remote cardiac monitoring offers continuous data on heart activity, allowing for the early detection of arrhythmias, optimized treatment timing, and improved sleep-related heart health management.

Research showed that children born via assisted reproductive technology were 36% more likely to develop heart defects.

The treatment aims to reduce prolonged QTc interval in patients with long QT syndrome.

Currently, Danon disease has a poor prognosis and does not have any pharmaceutical therapeutics for treatment or management.

The AHA acknowledged that complementary and alternative medicines are widely used by heart failure patients but warned that there is limited scientific evidence to support their efficacy.

Aaron Adkisson, PharmD, discusses the importance of considering factors such as age, gender, and cardiovascular comorbidities when monitoring and managing cardiotoxic risks in patients with cancer. also emphasizing patient education on recognizing early heart failure symptoms.

The use of devices like Apple watches may offer a more affordable and less burdensome modality to diagnose atrial fibrillation.

Parents of children with cancer had the highest risk of developing mental illness and cardiovascular diseases.

Edaravone and dexborneol sublingual tablets are an innovative first drug to be designed for treatment of stroke and granted this designation.

New insights into heart failure risks in Native American communities are highlighting the need to address social determinants of health.

Medication therapy management reimbursement can be a driving factor to work toward statin implementation in this patient group.

Investigators compare the impact of semaglutide for preserved ejection fraction and reduced ejection fraction, which both have different causes and responses to treatment.

Palliative care is crucial for safe and effective medication management to relieve symptoms and improve quality of life.

Joseph Saseen offers valuable insights into the implications of the added performance and quality measures for patients and health care providers.

Craig Beavers discusses significance of the 2024 update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure.

In recent years, telestroke services have transformed stroke care delivery, especially in rural or underserved areas.

Risk of developing anxiety or depression is highest within the first year after cardiovascular hospitalization.

Non-steroidal mineralocorticoid receptor antagonist, finerenone, demonstrated improved efficacy compared with existing steroidal treatment for patients.

Tirzepatide demonstrates statistically significant improvements in adult patients who have heart failure with preserved ejection fraction and obesity.